Predict your next investment

Wild Type company logo
FOOD & BEVERAGES | Meat, Fish, Seafood & Alternative Proteins
wildtypefoods.com

See what CB Insights has to offer

Founded Year

2016

Stage

Series A | Alive

Total Raised

$16M

Last Raised

$12.5M | 2 yrs ago

About Wild Type

Wild Type develops cultured salmon that is created directly from cells.

Wild Type Headquarter Location

953 Indiana Street

San Francisco, California, 94107,

United States

202-400-0574

Latest Wild Type News

BeyondSpring Announces Late-Breaking Oral Presentation of Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination Versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology 2021 Congress

Aug 31, 2021

New York, New York, UNITED STATES Topline results, released in early August, demonstrated improvement in overall survival (OS) for the combination vs. docetaxel alone as well as improvement in ORR, PFS, 24- and 36-month OS rates and incidence of Grade 4 neutropenia. NEW YORK, Aug. 31, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced a late-breaking oral presentation at the European Society for Medical Oncology 2021 Congress taking place virtually September 16-21, 2021. This will include the final intention-to-treat (ITT) dataset from the Company’s DUBLIN-3 Phase 3 registrational trial of their first-in-class lead asset, plinabulin, in combination with docetaxel vs. docetaxel alone for the treatment of 2nd/3rd line non-small cell lung cancer (NSCLC) patients with EGFR wild type. Additional Details: Title: A Global Phase (Ph) 3 Trial with the Plinabulin/Docetaxel (Plin/Doc) combination vs. Doc in 2nd/3rd Line NSCLC Patients (pts) with EGFR-wild type (wt) Progressing on a Prior Platinum-Based Regimen Session: Proffered Paper session - NSCLC, metastatic 2 Date: September 20, 2021 from 2:10 - 2:20 p.m. CEST Location: Channel 4 Presentation Number: LBA48 Speaker: Baohui Han, M.D., Ph.D, Professor in the Department of Respiratory Medicine, Shanghai Chest Hospital, China “The ESMO Congress is the perfect venue to present high-impact clinical oncology findings such as data from our successful DUBLIN-3 study that demonstrates plinabulin's ability to improve overall survival in 2nd/3rd line NSCLC patients,” said Dr. Lan Huang, co-founder, chairwoman and chief executive officer of BeyondSpring. “Importantly, the direct durable anti-cancer benefit shown by plinabulin in this study is a gateway to developing plinabulin as part of immuno-oncology combos in multiple cancer indications. In the coming months, BeyondSpring plans to apply for an NDA in the U.S. and China for the use of plinabulin in these NSCLC patients. This would add to the ongoing U.S. and China regulatory review of plinabulin in combination with G-CSF for the prevention of chemotherapy-induced neutropenia, which has a PDUFA date of November 30, 2021. We’ve had a tremendous year of milestones at BeyondSpring, and we are grateful to all of our collaborators for their great efforts in helping to bring plinabulin to cancer patients globally.” About Plinabulin Plinabulin, BeyondSpring’s lead asset, is a selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen presenting cell (APC) inducer. It is a novel, intravenous infused, patent-protected, NDA stage asset for CIN prevention and a Phase 3 anti-cancer candidate for non-small cell lung cancer (NSCLC). Plinabulin triggers the release of the immune defense protein, GEF-H1, which leads to two distinct effects: first is a durable anticancer benefit due to the maturation of dendritic cells resulting in the activation of tumor antigen-specific T-cells to target cancer cells, and the second is early-onset of action in CIN prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs). Plinabulin received Breakthrough Therapy designation from both U.S. and China FDA for the CIN prevention indication. As a “pipeline in a drug,” plinabulin is being broadly studied in combination with various immuno-oncology agents that could boost the effects of the PD-1/PD-L1 antibodies and re-sensitize PD-1/PD-L1 antibody-resistant patients. About BeyondSpring Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring’s first-in-class lead asset plinabulin, is being developed as a “pipeline in a drug.” It is filed for approval and has received Priority Review in the U.S. and China for the prevention of chemotherapy-induced neutropenia (CIN) with a PDUFA date of November 30, 2021 in the U.S.  Plinabulin and docetaxel combination has met the primary endpoint of extending overall survival in a global, randomized, active controlled Phase 3 study (DUBLIN-3) in 2nd/3rd line NSCLC (EGFR wild type). Additionally, it is being broadly studied in combination with various immuno-oncology regimens that could boost the effects of PD-1 / PD-L1 antibodies. In addition to plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform. Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring’s most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Investor Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Wild Type

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Wild Type in 2 CB Insights research briefs, most recently on Aug 9, 2021.

Expert Collections containing Wild Type

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Wild Type is included in 3 Expert Collections, including Agriculture Technology (Agtech).

A

Agriculture Technology (Agtech)

1,752 items

Companies that are using technology to make farms more efficient.

F

Food & Beverage

2,683 items

A

Alternative Proteins Startups

329 items

This Collection includes B2B and B2C companies developing alternatives to animal-derived proteins, including plant-based meat, dairy alternatives, lab-grown or cultured meat, and fermented proteins.

Wild Type Patents

Wild Type has filed 1 patent.

The 3 most popular patent topics include:

  • Biotechnology
  • Cell biology
  • Fatty acids
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/7/2018

Fatty acids, Stem cells, Transcription factors, Cell biology, Biotechnology

Application

Application Date

6/7/2018

Grant Date

Title

Related Topics

Fatty acids, Stem cells, Transcription factors, Cell biology, Biotechnology

Status

Application

Wild Type Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Wild Type Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.